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Mycosis fungoides is a form of cutaneous T-cell lymphoma (CTCL). Malignant CD4þ T cells have been
found to adopt the T-regulatory (Treg) cell phenotype and function. We present the case of a 66-year-old
man diagnosed with mycosis fungoides that was progressing from the plaque to the tumor stage. The
histopathological examinations showed that the Langerhans cell (LC) inﬁltration in the skin lesion of the
tumor stage was greater than that in the patch/plaque stage; the tumor stage lesions resembled LC
histiocytosis pathologically. The associations among LCs, apoptotic tumor cells, Treg CTCL cells, and
relevant cytokines are complex. Treg CTCL cells produce the immunosuppressive cytokines interleukin-
10 and transforming growth factor beta, which facilitate continuous recruitment of LCs and maintenance
of long-term dendritic cell immaturity, thereby explaining the remarkable LC inﬁltration in the tumor
stage samples from our patient. This phenomenon indicates that LCs accompanied by Treg CTCL cells
may play an important synergistic role in the tumor progression. The development of immunotherapy
directed against Treg CTCL cells and LCs overproduction and other immunosuppressive cytokines may be
a potent useful adjuvant and worthy of further investigation.
Copyright  2011, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Mycosis fungoides (MF) is a form of cutaneous T-cell lymphoma
(CTCL) that is probably elicited by various factors of exogenous or
endogenous origin. CTCL has been hypothesized to be a disease
caused by chronic antigen stimulation. The unlimited lymphoid cell
growth in CTCL is stimulated by immature dendritic cells (DCs).1 A
recent report suggests that CTCL cells, which are a malignant form
of CD4þ T cells, adopt T-regulatory (Treg) cell phenotypes (CD25þ,
CTLA-4þ, and FoxP3þ) and functions after undergoing stimulation
by DCs loaded with apoptotic T cells.2Case report
A 66-year-old man presented with multiple dusky-red to viola-
ceous, scaly patches/plaques, and nodules of varying sizes on the
trunk, scalp, and limbs. These lesions initially manifested 2 yearsgy, China Medical University
District, Taichung City 404,
e).
iwanese Dermatological Associatioback as annular erythematous or violet-red patches that were
treated as dermatitis. However, the skin lesions persisted,
disseminated, and enlarged with red-brown to purplish coloration
and irregular plaques and tumor formation. The tumor present on
the back also showed focal ulceration and necrosis. Laboratory
studies did not reveal leukocytosis with abnormal lymphocytes.
Serum lactate dehydrogenase and calcium were not elevated. No
osteolytic lesion was found in the image study. Both peripheral
blood smear and bone marrow examination were negative for
atypical lymphocyte inﬁltration. He had no hepatosplenomegaly
from the physical examination and image study. Serological
examination for human T-cell leukemia virus type-1 antibody was
negative. There were no further visceral involvements. MF pro-
gressing from the plaque to the tumor stage was clinically sus-
pected. The patient underwent skin biopsies for two separate skin
lesion samples from the patch/plaque stage (Figure 1A) and tumor
stage (Figure 1B).
Histopathologically, the patch/plaque stage lesion showed pat-
chy and focally diffuse inﬁltrates of small to medium-sized, irreg-
ular, and angulated atypical lymphoid cells involving the
perivascular and periadnexal spaces and the interstitium of the
dermis (Figure 2A). We also observed foci of epidermal permeationn. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 1 Skin specimens from two separate lesions: (A) patch/plaque stage and (B) tumor stage of mycosis fungoides.
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In the immunohistochemical analysis, the atypical lymphoid cells
were positive for CD4 (Figure 2C) but negative for CD8 and CD20
(not shown). The presence of numerous number of CD1a-postive
histiocytoid cells with reniform nuclei was identiﬁed mainly in
the intraepidermal and little in the dermal perivascular regions
(Figure 3C). A constellation of clinical manifestations and histo-
pathological and immunohistochemical features suggests diag-
nostic of patch/plaque stage MF with variant intraepidermal and
dermal perivascular Langerhans cells (LCs) inﬁltrates.
However, the tumor nodule showed dense inﬁltration of dermal
aggregates of atypical lymphoid cells, numerous large histiocytoid
cells with grooved, reniform nuclei closely interspersed among
tumor cells, and scattered eosinophils (Figures 3A and 3B). The
histiocytoid cells showed membranous staining for CD1a
(Figure 3D) and cytoplasmic staining for S-100 protein densely
distributed in the epidermis and entire dermis (not shown). This
conﬁrmed their identity as LCs. In the present case, a large number
of CD68-positive cell inﬁltrates mainly in the dermis was also
observed (not shown). Based on the overall features, it was diag-
nostic of tumor stage MF with numerous LC proliferations. He
received regular medication treatment with topical and systemic
steroids, methotrexate, and phototherapy. There were no further
visceral involvements. Unfortunately, the patient died of pneu-
monia and sepsis 7 months later.
Discussion
Cutaneous DCs, including dermal and epidermal DCs, play an
important role in the induction of immune responses against tumor
cells. When the immune system encounters emerging tumor cells,
regional tissue immature DCs ingest tumor cells or their tumor
antigens. Then, the tumor-speciﬁc antigens are processed and
displayed by the Class I and Class II major histocompatibility
complex (MHC) molecules on the DCs. These fragmented peptides
may be presented to cytotoxic T-cells. The process of induction of
an antitumor T-cell response is called cross-presentation. Eventu-
ally, tumor-speciﬁc CD8þ cytotoxic T lymphocytes gain the ability
to recognize and kill tumor cells by inducing them to undergo
apoptosis. At present, the activation of naïve CD8þ T cells to
differentiate into active cytotoxic T-lymphocytes is known to
require recognition of antigens, costimulatory signals, and perhapshelp from class II MHC-restricted CD4þ T cells. In a previous con-
ducted in vitro study, apoptotic MF cells were recognized as tumor-
speciﬁc antigens by the immune system in the latter phase of the
tumor growth.3
It is of particular interest that tumors are frequently inﬁltrated
with DCs and the presence of an increased number of DCs within
the tumor has been postulated to indicate a better prognosis in
certain cancers.4 However, LCs, which constitute a subset of DCs
and function as antigen-presenting cells (APCs), are important
regulators of T-cell immunity and most prevalent in the epidermis.
LCs are characterized by positive staining for CD1a, S-100 protein,
and, more speciﬁcally, langerin, which is a LC-speciﬁc C-type lectin
and imparts a speciﬁc functional role to LCs in facilitating antigen
presentation by CD1a.5 In the other study, of meaningful ﬁnding is
that the proportion of LCs intermingled with malignant lymphoid
cells in the tumor stage inﬁltrate is signiﬁcantly higher than that in
the patch/plaque stage inﬁltrate.4 In our case, the ﬁndings of
immunohistochemical studies are consistent with those of
previous reports; these studies also showed that the number of LCs
in the tumor stage MF lesions is signiﬁcantly higher than the cor-
responding number in the patch/plaque stage samples. The pres-
ence of pronounced inﬁltrates of CD1aþ/S-100þ LCs among atypical
lymphoid cells in the tumor stage MF lesions may lead to misin-
terpretation as LC histiocytosis (LCH) histologically. It brings us
a big puzzle as well.
To the best of our knowledge, LCH is a different disease entity
caused by the inﬁltration of LCs in one or more organs, among
which cutaneous involvement is traditionally considered to
portend a multisystemic involvement and has a poor prognosis.6
Previous studies demonstrated that LCH is characterized by clonal
proliferation. The LCs of LCH form a monoclonal population, indi-
cating that LCH is neoplastic.7 However, other studies state that the
excess of LC in lymphoproliferative disorders or lymphoms is
polyclonal.8,9 This may support that the accumulation of LC in this
circumstance is in favor of a reactive nature. Elsewhere, the absence
of thrombocytopenia, hepatosplenomegaly, or pulmonary inﬁl-
treates clinically is deﬁnitely against the diagnosis of LCH.
The roles of diverse cutaneous DC populations in the induction
of immunity and tolerance are also currently popular and under
research. There is some indication that dermal DCs and LCs might
have different roles in the immune responses.10 The role of cuta-
neous LCs in inducing T-cell-mediated immune responses appears
Figure 2 Histopathological and immunohistochemical features. The typical features of
the patch/plaque stage lesion are composed of diffuse inﬁltrates of atypical lymphoid
cells in the dermis, (A) foci of epidermatropism, and (B) Pautrier’s microabscess. (C)
Immunohistochemical staining revealed CD4-positive cells. Original magniﬁcation: (A)
hematoxylin and eosin (H&E), 200; (B) H&E, 400; (C) 400.
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dermal DCs may elicit humoral responses.10 Immature DCs should
be restricted to inﬂamed epithelium at the site of antigen entry.
When encountering with foreign antigens, DCs use their surface
receptors to capture and endocytose foreign antigens. The activated
DCs are on the way of migration through lymphatic circulation toregional lymph nodes. During the route of migration, DCs mature
from cells capable of capturing antigens into APCs. After reaching
the hilum of lymph node, APCs are quickly directed to T cells zones
by chemoattracting cytokines produced in the microenvironment
of T-cell zones. Although APCs encounter with naïve T cells, the
former are efﬁcient at presenting MHC class II-restricted foreign
peptides to the latter, resulting in activation of a subset of effector T
cells.11 The existence of a novel langerinþ DC subset in the dermis
has been identiﬁed that is independent of epidermal LCs by several
study groups recently. Instead of LCs, langerinþ dermal DCs are
suggested to be critical for the initiation of efﬁcient T cell response
in contact hypersensitivity study using animal model.12,13 The
ﬁnding seems contradictory to original recognition of LCs function.
In brief summary, DCs will go through a maturation process, so
their surface molecules may change into distinct proﬁles. Impor-
tantly, to recognize the cellular behavior of DCs may give us better
insight into how this process can occur.
In recent years, a population of T cells with the
CD4þCD25þFoxP3þ phenotype, that is, Treg cells, has been shown
to play a key role in the suppression of immune response.14 Berger
et al2 concluded that the malignant cells of CTCL adopt Treg cell
phenotype and functions. Treg CTCL cells are an important pop-
ulation that plays a crucial role in the maintenance of tumor self-
tolerance. From in vitro studies, loading of immature DCs with
apoptotic CTCL cells and exposing them to CD4þ CTCL cells would
result in clonal expansion of Treg CTCL cells with upregulation of
cytoplasmic cytotoxic T lymphocyte antigen-4 (CTLA-4), FoxP3, and
membrane CD25. The inductions of all these molecules lead to the
differentiation of Treg cells along with inhibition of normal T-cell
poiesis.15
These Treg CTCL cells may engage T-cell inhibitory pathways
mediated by secretion of interleukin-10 (IL-10) and transforming
growth factor beta (TGF-b) and expression of CTLA-4.4,16 IL-10
produced by Treg CTCL cells maintains long-term DC immatu-
rity, thereby ensuring continued phagocytosis of apoptotic cells
and further CTCL cell replication.11 In other words, “immature
DCs” are able to support CTCL cell replication. After maturation,
DCs would eventually result in degranulation and death of DCs,
which is rapidly followed by death of CTCL cells.1 Secretion of
TGF-b by Treg CTCL cells can also incite the differentiation of
monocytes and CD34 precursors into immature DCs, thereby
facilitating continual recruitment of LCs.17 CTLA-4, a membrane
molecule of Treg cells, also plays an important role in the down-
regulation of immunosurveillance.16 The mechanism of immuno-
pathology in CTCL is regulated by an intricate pathway that is closely
associated with the interactions among LCs, apoptotic tumor cells,
Treg CTCL cells, and relevant cytokine expression. This ﬁnding may
imply that remarkable LC inﬁltrationwithin tumor nodules, like that
observed in our patient, may contribute to the growth of Treg CTCL
cells and result in the progression of patch/plaque stageMF to tumor
stage MF.
From a therapeutic point of view, it already shows that, in the
in vivo study, depletion of these Treg cells by administration of
anti-CD25 monoclonal antibody has indeed suppressed growth of
a variety of different tumors.18,19 The elimination of CD25þ Treg
cells facilitates long-term CD4þ T cell-mediated tumor immunity
and is a potent useful adjuvant in immunotherapy.18 The devel-
opment of certain receptor-speciﬁc antagonists may inhibit the
overproduction of LCs and excessive immunosuppression medi-
ated by IL-10, TGF-b, and other cytokines produced by Treg CTCL
cells. Perhaps an immunotherapy strategy designed for interrup-
tion of the pathway of LCs and Treg CTCL cell overproduction
possibly resulting in refractory MF is worthy of further investiga-
tion and may contribute to the development of new therapeutic
approaches.
Figure 3 Histopathological and immunohistochemical features. (A and B) The tumor stage lesion shows dense inﬁltration of histiocytoid cells with grooved, reniform nuclei
interspersed among atypical lymphoid cells and scattered eosinophils, which mimics the features of Langerhans cell histiocytosis. (C) Numerous CD1a-positive cells is seen in the
patch/plaque stage lesion. (D) The histiocytoid cells are positive membranous staining for CD1a in the tumor stage lesion. Original magniﬁcation: (A) hematoxylin and eosin
(H&E), 200; (B) H&E, 400; (C) 100; and (D) 400.
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CTCL cells may play an important synergistic role in the tumor
progression to amore advanced stage ofMF. Thehistologicalﬁnding in
nodular lesion of tumor stage MF shows prominent LC proliferation
thatmay cause a difﬁcult distinction between reactive LC proliferation
and LCH. The excess of LC in thismicroenvironment is presumed to be
polyclonal and reactive in nature. As a general rule, mature DCs may
express a defensive immune response against tumor cells. On the
contrary, the antitumor immunity may deviate to the tumor-
progression state under the inﬂuence of LCs, apoptotic tumor cells,
and Treg CTCL-cell differentiation. CD4þCD25þ Foxp3þ Treg CTCL cells
may inhibit the generation of immune responses and hamper
the development of effective tumor immunity. The excessiveimmunosuppression mediated by intricate interaction between LCs,
apoptotic cells, and Treg CTCL cells and accumulation of genetic
alteration of tumor cells presumably contributes to the tumor
progression of CTCL.References
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